TrumpRx: What the Lilly and Novo Nordisk Price Deals Mean for Weight Loss Drug Costs
The Trump administration announced deals with Eli Lilly and Novo Nordisk to significantly reduce the cost of weight loss medications through TrumpRx. Here's what we know and what it means for people taking semaglutide or tirzepatide.
What Was Announced
Both major GLP-1 drug manufacturers have agreed to reduced pricing for their weight loss medications through TrumpRx:
- Novo Nordisk — semaglutide (Ozempic, Wegovy)
- Eli Lilly — tirzepatide (Mounjaro, Zepbound)
The exact discount structures haven't been fully detailed yet, but the announcement signals a significant shift in the affordability landscape for weight loss medications.
Current Pricing Context
To understand why this matters, here's what these drugs cost today:
| Drug | List Price (Monthly) | With Savings Programs |
|---|---|---|
| Wegovy (semaglutide) | ~$1,349 | Varies |
| Zepbound (tirzepatide) | ~$1,069 | As low as $25 (Lilly card) |
| Compounded semaglutide | $150–500 | N/A |
| Compounded tirzepatide | $349–699 | N/A |
For millions of Americans without insurance coverage for weight loss medications, these list prices are simply out of reach.
What This Could Change
If TrumpRx delivers meaningful discounts:
- 1Broader access — People who couldn't afford brand-name drugs may now have an option
- 2Pressure on compounding — If brand-name prices drop substantially, the compounding market faces more competition
- 3Insurance dynamics — Government pricing benchmarks could influence private insurance coverage decisions
- 4Political signal — Weight loss drugs are now a political priority, not just a health one
What We Don't Know Yet
- Exact prices through TrumpRx
- Eligibility criteria — who qualifies
- Launch timeline — when the platform goes live
- Whether this affects compounded drug availability — the FDA's stance on compounding during shortage periods remains complex
Also This Week: Oral Semaglutide Pricing
GoodRx announced pricing for oral semaglutide through its telemedicine service:
- 1.5 mg and 4 mg doses
- $149/month (rising to $199 after April 2026)
- 9 mg and 25 mg doses
- $299/month
Oral semaglutide (the pill version of Wegovy) was approved for weight loss in January 2026. A sub-$300/month oral option is a significant development for patients who prefer pills over injections.
Our Take
The cost conversation around weight loss peptides is the single biggest factor determining who gets access to these medications. Clinical efficacy is no longer the debate — semaglutide and tirzepatide work. The question is whether the people who need them can afford them.
Government involvement in pricing, oral formulations, and expanding compounding access are all moving in the right direction. We'll update this post as more details emerge from TrumpRx.
Sources
- AJMC. “Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices.” March 23, 2026.
- AJMC. “GoodRx to Match Novo Nordisk Price for Oral Semaglutide.” March 28, 2026.
Educational content only. This does not constitute medical advice. Consult a qualified healthcare professional before making any health decisions.